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The 21st Workshop on Vitamin D was held at the Centre de Convencions Internacional de 
Barcelona (CCIB) from May 16-19, 2018. The Workshop was organized by Dr Martin 
Hewison (Chair, University of Birmingham, Birmingham, UK) with the invaluable support of 
Dr JoEllen Welsh (CFO, SUNY Albany, USA) and Roxanne Hall (Meetings Plus). Invited 
presentations and topical sessions were chosen by the Workshop Executive Committee, with 
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input from the Program Advisory committee (http://www.vitamindworkshop.org). The 
Workshop, which attracted 252 attendees from 41 countries, began the evening of May 16 
with an opening reception and 24 Plenary Poster presentations. The following three days were 
filled will exciting science, divided into 12 sessions of symposium and promoted abstract oral 
presentations covering topics in basic science, clinical research and epidemiology, 158 poster 
presentations. Delegates who presented at the Workshop were invited to submit manuscripts 
for peer reviewed publication in this special edition of the Journal of Steroid Biochemistry and 
Molecular Biology. Each submitted manuscript was peer reviewed according to Journal 
standards. Guest editors were Dr Martin Hewison (University of Birmingham, UK) and Dr 
James Fleet (Purdue University, USA). Topical summaries of all oral sessions are presented 
below, and include links to manuscripts accepted for publication in the special edition of the 
Journal of Steroid Biochemistry and Molecular Biology.  
 
The first day started with opening remarks by the Chair, Dr Martin Hewison, followed by 
Session I entitled the Year in Vitamin D: Basic and Translational chaired by Dr Carsten 
Carlberg (University of Eastern Finland) and presented by Dr Marie Demay (Harvard Medical 
School, and Massachusetts General Hospital). Dr Demay provided an excellent overview of 
some of the key publications within the vitamin D field in the years 2017 and 2018, focusing 
primarily on basic science research. She started with a report that vitamin D receptor (VDR) 
regulates microbiota-dependent inflammation of gut mucosa by suppressing the apoptosis of 
intestinal epithelial cells, i.e. VDR plays a significant role in attenuating the inflammatory 
response in the intestine [1]. Another paper showed that the cytokines IL12 and IL18, which 
synergize to promote TH1 cell differentiation, trigger anti-microbial response against 
tuberculosis up-regulate VDR gene expression and induce in this way the anti-microbial VDR 
target genes CAMP and DEFB4A in macrophages [2]. In contrast, schistosomiasis-induced 
liver fibrosis is promoted, when the miRNA miR351 down-regulates VDR expression [3]. Thus, 
interferon γ-mediated down-regulation of miR351 and/or vitamin D analog-stimulated VDR 
activation may be an effective treatment of the worm-induced liver fibrosis. miR675, which co-
locates with the H19 gene encoding for a long ncRNA, is another miRNA that decreases VDR 
expression. However, in colon cancer cells VDR is not repressed, when the biologically active 
form of vitamin D, 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3), down-regulates the MYC gene, 
which encodes for a transcription factor prominently up-regulating the H19 gene [4]. In renal 
cell carcinoma cell lines VDR suppresses proliferation and metastasis via affecting the 
expression of the TRPV5 gene encoding for a calcium-selective channel [5]. In multiple 
myeloma cells 1,25(OH)2D3 can induce an osteoclast-like phenotype via the induction of 
cytoskeleton remodeling and up-regulation myeloid and osteoclast markers [6]. This reinforces 
the bone erosive activity of multiple myeloma cells. Dr Demay also discussed a paper 
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describing that VDR associates in a ligand-dependent manner with nuclear matrix proteins via 
the hinge region between its DNA-binding and ligand-binding domain [7]. Therefore, during 
interphase VDR locates in the nucleus but during mitosis in the cytoplasm. A large pharmacore 
docking screen identified a novel non-steroidal VDR agonist showing potent cardio-protective 
effects while being devoid of hypercalcemia [8]. Another non-steroidal VDR agonist showed 
to significantly inhibit chronic pancreatitis in vivo without increasing serum calcium levels [9]. 
Dr Demay showed special interest in an article reporting the knockout of the 25-hydroxylase 
Cyp2r1 in zebrafish [10], which resulted in decreased somatic growth and obesity. The results 
of this study suggested that vitamin D signaling promote fatty acid oxidation by inducing the 
expression of the co-activator Pgc1a. The topic “metabolism” was covered by a paper 
indicating that the vitamin D compounds, 1α-hydroxyvitamin D3, 1α-hydroxyvitamin D2 and 25-
hydroxyvitamin D3 (25(OH)D3) lower cholesterol in vivo in hypercholesterolemic mice via the 
activation of 1,25(OH)2D3 [11]. Finally, Dr Demay discussed a report on the effects of early life 
vitamin D exposure on later skeletal health [12]. A mouse model system was used to 
demonstrate that early life vitamin D depletion results in abrogation of the response to 
mechanical loading, with consequent reduction in bone size, mass and strength during both 
childhood and adulthood. 
 
The subject of Session II was Vitamin D and Bone Disease and was chaired by Dr Roger 
Bouillon (Katholieke Universiteit Leuven). Dr Wolfgang Högler (University of Birmingham) 
gave an excellent overview of the increasing problem of nutritional rickets. He discussed how 
many governments fail to adjust prevention programs for rickets in relation to the changes in 
population demographics. Indeed, people with dark skin are immigrating into countries with 
high latitude, resulting in low production of vitamin D. This vitamin D deficiency results in 
rickets and hypocalcemic complications with even cardiac deaths in infants. Infantile vitamin 
D supplementation programs are thus essential and monitoring of supplementation is needed 
[13]. Dr Paul Anderson (University of South Australia) discussed several novel aspects of 
vitamin D metabolism in mature osteoblasts. The focus was especially on the role of local 
synthesis of vitamin D in these cells. Two complementary conditional transgenic mouse 
models were used, one with inactivation of Cyp27b1, the other with overexpression of the 
gene. Both models came to the same conclusion, indicating that Cyp27b1 activity in 
osteoblasts promotes bone formation. Adequate serum 25(OH)D3 levels are thus required for 
bone health [14]. Dr Jeffery Roizen (Children’s Hospital of Philadelphia) described a novel 
genetic form of vitamin D deficiency in two patients with early-onset rickets, with a mutation in 
CYP3A4 resulting in a 10-fold greater enzyme activity. The enzyme activity of CYP3A4 was 
even higher activity than of CYP24A1 (24-hydroxylase) in catabolizing vitamin D metabolites, 
leading to enhanced elimination of vitamin D. Dr Lieve Verlinden (Katholieke Universiteit 
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Leuven) discussed the role of VDR signaling in osteocytes during lactation. Mice with 
inactivation of VDR in osteocytes have normal bone and calcium homeostasis. During 
lactation however, bone loss was smaller in the mutant lactating mothers compared to wild-
type. This decreased calcium release from bone in the mother had no effect on bone growth 
or mass in the offspring. These findings suggest compensation by other organs, although no 
major effects were observed in the intestine or kidney. Thus, VDR signaling in osteocytes 
contributes to the bone loss observed during lactation. Dr Arnaud Molin (Caen University 
Hospital) presented that in a cohort of patients with hypercalcemia and suspected CYP24A1 
deficiency, they tried to find differences in the biochemical data that would reflect mutations in 
CYP24A1 rather than in renal sodium-phosphate co-transporters SCL34A1 and SCL34A3, 
which can give a similar clinical phenotype. Patients with CYP24A1 and SLC34A1 mutations 
had similar biochemical phenotypes, but patients with SLC23A3 mutations showed lower 
serum calcium and phosphate levels.  
 
Session III focused on Bioinformatics and was chaired by Dr John White (McGill University 
Montreal) and Dr Martin Tenniswood (Albany University New York). As with all fields, 
genomic technologies and approaches are applied frequently to understand the actions of the 
VDR) in terms of where it binds, what genes are regulated and how this changes across cell 
types and disease states. This session illustrated where progress is being made, and 
challenges remain. Firstly, Dr André G. Uitterlinden (Erasmus Medical Center, Rotterdam) 
gave an overview of what Genome Wide Association Studies (GWAS) can reveal about how 
genetic variation impacting vitamin D signaling is detectible in large cohorts. For example, Dr 
Uitterlinden is the PI of a large cohort of 20,000 elderly patients (the Rotterdam Cohort) in 
which GWAS approaches have been applied to test associations between aspects of vitamin 
D signaling, for example serum levels of 25(OH)D3 and the pre-disposition of aging-related 
syndromes including those related to bone health. Genomic approaches are also being 
applied to cell-base studies with the goal to understand the major or most significant pathways 
identified. Next, Dr Susan Coort (Maastricht University) gave an overview of the challenges 
in pathway analyses and illustrated how software her group has developed can be used to 
illustrate and identify the significant pathways. For example, her group and colleagues have 
developed tools including WikiPathways and PathVisio to help identify the important 
components of activated pathways in response to vitamin D treatments [15].  
 
Bioinformatic and analytical approaches to better understand different aspects of VDR 
signalling were then presented. Dr Carsten Carlberg (University of Eastern Finland) 
addressed the time-dependent nature of vitamin D signaling and has used so-called machine 
learning to integrate multiple high-dimensional data sets (e.g. receptor binding, changes in 
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histone modifications and changes in gene expression) to identify sub-sets of relationships 
that support a choreographed aspect to VDR signaling that is integrated with other 
transcription factors to bring about complex phenotypes such as cell differentiation [16]. 
Finally, Dr Moray Campbell (Ohio State University) examined differences between African 
American and European American prostate cancer patients in terms of which patients had 
stable disease, compared to those whose disease progressed. These studies revealed key 
roles for several microRNAs, uniquely in African American patients, and integration with 
publicly available data strongly supported roles for VDR to be involved in the regulation of 
these genes.  
 
In Session IV the workshop addressed recent developments in Vitamin D and Cancer 
chaired by Dr George Studzinski (Rutgers, New Jersey Medical School) and Dr JoEllen 
Welsh (Albany University New York). Dr Alberto Muñoz (Instituto de Investigaciones 
Biomédicas, CSIC-UAM and CIBERONC Madrid) provided a state-of-the-art overview of the 
actions of vitamin D in colon cancer [17]. Dr Muñoz began by highlighting the epidemiology 
linking vitamin D-deficiency with the incidence and mortality of colon cancer. A role for vitamin 
D in colon cancer is further supported by the fact that VDR is abundantly expressed in cells 
from the gastrointestinal tract. However, it is important to recognise that levels of VDR (and 
also the vitamin D-activating enzyme CYP27B1) may be down-regulated in colon cancer 
tissue, whilst catabolic enzymes such as CYP24A1 are up-regulated. The over-arching effect 
is to promote resistance to 1,25(OH)2D3 in colon cancer. Despite this, studies in vitro have 
shown that 1,25(OH)2D3 inhibits the proliferation of colon cancer cells and the role of the 
Wnt/β-catenin pathway in this process was highlighted, with 1,25(OH)2D3 acting to inhibit 
elevated Wnt/β-catenin signalling in colon cancer. Dr Muñoz also described recent studies in 
which organoids using cells from colon cancer patients have been used to demonstrated the 
anti-neoplastic effects of 1,25(OH)2D3. Likewise, a key new facet of vitamin D action in colon 
cancer is its role in mediating anti-inflammatory responses against infiltrating immune cells in 
colon cancer. Finally, Dr Muñoz highlighted the growing interest in a role for vitamin D in 
mediating gastrointestinal responses to vitamin D and the role that this may play in the 
initiation and progression of colon cancer.  
 
Dr Gilles Laverny (IGBMC-CERBM GIE) described the role of vitamin D in controlling 
prostatic pre-cancerous lesions. The presentation focused on phosphatase and TENsin 
homolog (PTEN) as the most frequently mutated or deleted tumor-suppressor in prostate 
cancer. Mice with prostatic deletion of the PTEN gene in adults show develop prostatic 
intraepithelial neoplasia (PIN) within a month following PTEN knockout. When crossed with 
VDR knockout mice the PTEN knockout mouse showed enhanced prostate size and PIN, 
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indicating that VDR signalling impacts PIN progression. Conversely, treatment of PTEN 
knockout mice with a 1,25(OH)2D3 analog reduced proliferation and increase apoptosis of PIN 
cells. Dr John White (McGill University Montreal) described studies of vitamin D and the 
tumor-suppressor and E3 ligase FBW7. 1,25(OH)2D3 rapidly induces VDR-FBW7 interaction 
with c-MYC, promoting proteasomal degradation of c-MYC on DNA. Similar observations were 
also made for other FBW7 targets such as cyclin E, c-Jun and MCL1. FBW7 depletion 
diminished the anti-proliferative effects of 1,25(OH)2D3 via an apparent inhibition of DNA-
binding of liganded VDR, demonstrating a novel mechanism by which vitamin D can exert anti-
cancer responses.  
 
New data on the epidemiology of vitamin D and cancer were presented by Dr Fiona 
O’Sullivan (Trinity College Dublin) who described studies of a cohort of samples from the UK 
Biobank (n=500,000). Internet based emissions monitoring was used to calculate the UVB 
exposure of each participant. When comparing highest to lowest tertile of UVB exposure, there 
was decreased risk of colorectal, breast and lung cancer, indicating that there was an inverse 
correlation between UVB radiation exposure and risk of common cancers, with vitamin D being 
likely factor in this association. The final presentation in Session IV explored the potential use 
of a 1,25(OH)2D3 analog, (Inecalictol), to treat aggressive, triple-negative breast cancer 
(TNBC). Dr Justine Vanhevel (Katholieke Universiteit Leuven) described how in TNBC cells 
in vitro, Inecalictol potently suppressed cell proliferation and this effect was enhanced in 
combination with a CDK4/6 inhibitor Palbociclib. Thus combination therapy with Palbociclib 
and Inecalictol may provide a novel treatment strategy for TNBC. 
 
The first full day of the meeting ended with Session V focused on Vitamin D, Immunology, 
and Respiratory Disease chaired by Dr Margherita Cantorna (Pennsylvania State 
University) and Dr Carlos Bernal-Mizrachi (Washington University). Dr Adrian Martineau 
(Queen Mary University London) provided an introduction to the antimicrobial properties of 
vitamin D, including the induction of antibacterial proteins, autophagy and intracellular iron-
regulatory pathways by innate immune cells such as macrophages. The importance of these 
mechanisms in mediating anti-microbial responses to vitamin D was further underlined by 
localised conversion expression of the enzyme 1α-hydroxylase in monocytes and 
macrophages, thereby enabling antimicrobial responses to 25(OH)D3 with this effect being 
compromised under conditions of vitamin D-deficiency. Dr Martineau described recent meta-
analyses for the effect of vitamin D on acute upper respiratory infection. By using 
disaggregated individual participant data from multiple vitamin D supplementation studies from 
around the world, it was possible to show that vitamin D supplementation decreased acute 
respiratory infections. Notably this anti-infection response to vitamin D supplementation was 
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most pronounced in individuals who were vitamin D-deficient (< 25 nmol/L serum 25(OH)D3) 
before treatment, and in those who did not receive large bolus doses (>30,000 IU) of vitamin 
D supplementation [18]. At a mechanistic level, Dr Martineau pointed out that while vitamin D 
was an effective anti-bacterial agent for respiratory pathogens such as Mycobacterium 
tuberculosis (M. tb.), the causative organism for tuberculosis. However, it appears that M. tb 
itself can corrupt antibacterial responses to vitamin D by stimulating dysregulation of vitamin 
D metabolism in target cells such as macrophages. 
 
Dr Wim Janssens (Katholieke Universiteit Leuven) described the link between vitamin D and 
chronic obstructive pulmonary disease (COPD). Although COPD is strongly associated with 
cigarette smoking, the initiation and development of COPD has also been linked to vitamin D-
deficiency. This is due to the fact that morbidity and mortality from COPD involve repeated 
airways infection, inflammation and skeletal muscle dysfunction, all of which may be 
influenced by vitamin D. In particular, antibacterial and anti-inflammatory responses to serum 
25(OH)D3 by cells from the immune system provide a mechanistic basis for vitamin D 
supplementation in COPD patients. Epidemiology has linked low serum 25(OH)D3 status, with 
impaired lung function, risk of COPD and accelerated lung function decline. Recent vitamin D 
supplementation trials have demonstrated clinically important risk reductions for acute COPD 
exacerbations, particularly for those patients who were vitamin D-deficient prior to 
supplementation. The connection between COPD and other diseases such as lung cancer 
and cardiovascular disease means that new strategies to manage vitamin D-deficiency in 
COPD patients are needed. 
 
Dr Carsten Carlberg (University of Eastern Finland) detailed the importance of epigenetics 
in mediating immune responses to vitamin D. In a study carried out in vivo using healthy adults 
supplemented with a single bolus dose of vitamin D (80,000 IU) showed that that rise in serum 
25(OH)D3 by in average 15 nmol/L was sufficient for statistically significant alterations in 
chromatin accessibility at some 850 genomic loci after only 1 day of supplementation [19]. 
Notable clusters for vitamin D supplementation-induced chromatin modifications were in the 
human leukocyte antigen (HLA) region of chromosome 6. Dr Richard Mellanby (University of 
Edinburgh) described studies in which his team had explored the link between vitamin D-
deficiency and autoimmune diseases such as multiple sclerosis. They showed that a key role 
of vitamin D is to modulate the priming of naïve T cells via actions on the dendritic cells that 
present antigen to T cells. Using bone marrow-derived dendritic cells they identified 7 genes 
that were regulated by 1,25(OH)2D3 in the presence of absence of the immunogen 
lipopolysaccharide. This groups of genes included CD31, a member of the immunoglobulin 
superfamily. CD31 gene knockdown of increased the ability of 1,25(OH)2D3-treated dendritic 
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cells to prime T cell activation, indicating that CD31 was a crucial component of the 
mechanism by which 1,25(OH)2D3 is able to regulate antigen presentation and T cell priming 
via dendritic cells.  
 
Dr Jef Serré (Katholieke Universiteit Leuven) further expanded the earlier discussion of 
vitamin D and COPD by describing studies of the impact of vitamin D-deficiency and cigarette 
smoke exposure on lung inflammation and bacterial clearance after acute infection with Non-
typeable Haemophilus influenza (NTHi) using a mouse model. The interesting observation 
was that, independent of cigarette smoke, bacterial clearance in NTHi mice was improved with 
vitamin D deficiency. The proposed mechanism for this effect was through enhanced 
inflammation and resulting stimulation of antibacterial proteins, or via increased breakdown of 
extracellular matrix [20]. In the final presentation of this session, Dr David Joliffe (Queen 
Mary University London) completed the series of presentations on vitamin D and COPD by 
describing a systematic review and meta-analysis using individual participant data. Vitamin D 
supplementation did not affect the overall rate of moderate/sever exacerbations of COPD. 
However, pre-specified sub-group analysis showed that significant protective effects of vitamin 
D supplementation were observed in COPD patients with baseline serum 25(OH)D3 of less 
than 25 nmol/L, but not those above 25 nmol/L.  
 
The second full day of the meeting began with Session VI on Vitamin D and Nutrition, 
chaired by Dr Inez Schoenmakers (University of East Anglia) and Dr Kevin Cashman 
(University of Cork, Ireland). Dr Mairead Kiely (University College Cork) represented the 
ODIN consortium (Food-based solutions for optimal vitamin D nutrition and health throughout 
life). Her presentation focused on integration of ODIN results using its specialized food 
composition dataset for vitamin D, dose-response data from RCTs with vitamin D and vitamin 
D fortified and bio-fortified foods and data from 10 nationally representative dietary surveys 
from 4 European countries. These data were used to conduct modelling experiments to model 
and demonstrate the feasibility of achieving vitamin D intakes according to recommendations 
without increasing the risk of excessive intakes. Further modelling with different thresholds of 
25OHD, considered country-specific UVB availability and the plasma 25(OH)D3 response to 
vitamin D intake, showed how (bio) food fortification strategies may be applied to increase 
vitamin D status across the population and prevent vitamin D deficiency without reaching toxic 
levels of 25(OH)D3. Dr Jakob Linseisen (Ludwig-Maximilians-Universität, München and 
IARC-WHO, Lyon) presented data from the European Prospective Investigation into Cancer 
and Nutrition (EPIC) consortium. He addressed the complexity of the dietary assessment 
across different countries. He reported a North (high) – South (low) gradient in vitamin D intake 
from both food and supplements. Dr Linseisen critically reviewed the apparent conflicting 
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associations between disease outcomes and dietary vitamin D intake versus plasma 
25(OH)D3 concentrations found in observational studies. He acknowledged that this may be 
due to the limited influence of dietary intake of vitamin D on vitamin D status. He called for 
meta-analyses of observational studies assessing the relationship between vitamin D intake 
and status and disease outcomes, particularly for those for which a RCT design is unsuitable.  
 
Dr Nick Shaw (University of Birmingham) presented on behalf of the British Paediatric 
Surveillance Unit Nutritional Rickets Surveillance Group (BPSU). He described the results of 
an in-depth investigation standardized according to BPSU criteria of cases of nutritional rickets 
(n=125) identified through surveillance amongst 3500 pediatricians in the UK and Ireland. The 
national estimated annual incidence was 0.48 cases per 100,000 children under 16 years, with 
the majority presenting under the age of 5 years (annual incidence 1.39 per 100,000). The 
incidence was higher in boys than girls and the majority were of Black and South Asian 
ethnicity. The majority of affected children did not meet the recommended intake of vitamin D 
or receive supplementation. Also, a number of non-vitamin D deficient cases were identified, 
in which calcium deficiency was suspected. Dr Shaw called for a better UK health policy to 
increase the uptake of vitamin D supplement use and adequate calcium intake to prevent 
nutritional rickets. Dr Javeria Saleem (University of the Punjab, Lahore) on behalf of an 
international consortium from London, UK and Auckland, New Zealand) presented the results 
of a 8-week randomized intervention study with adjunct administration of vitamin D3 (200,000 
IU at 2 and 4 weeks) or placebo with standard treatment of children aged 6-58 months with 
uncomplicated severe acute malnutrition in Pakistan. Although no effect on the primary 
outcome was found (the proportion of participants gaining >15% of baseline weight after 8 
weeks of treatment), co-administration of vitamin D increased weight-for-height gain and 
reduced the proportion of children with indices of delayed development. Dr Jette Jakobsen 
(National Food Institute, Technical University of Denmark) presented results from a 
randomized cross-over intervention study with 10 µg/day vitamin D3, 25(OH)D3 or vitamin D2 
on 25(OH)D levels in serum. The design allowed the elimination of inter-individual differences 
on the dose-response and showed significant differences in the 6-week increase in serum 
25(OH)D between different forms (compared to vitamin D3, vitamin D2: 0.44 and 25(OH)D3: 
1.5).  
 
Dr Hajar Mazahery (Massey University, New Zealand, on behalf of an international 
consortium from Australia and Harvard University) presented data from the VIDOMA trial 
evaluating the effects of 1-year supplementation with Vitamin D, Omega-3 or a combination 
of Vitamin D and Omega-3 compared to placebo on symptoms of Autism Spectrum Disorder 
(measured as irritability and hyperactivity scores). The irritability scores significantly 
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decreased in all treatment groups whereas the hyperactivity score only significantly decreased 
in the group given vitamin D. Analyses of post-supplementation plasma concentrations 
reflecting the response to the intervention (the plasma Omega-3 index and 25(OH)D3) 
suggested a relationship between the achieved concentrations and irritability and hyperactivity 
scores.  
 
Session VII on Non-Calcemic Target Tissues for Vitamin D was chaired by Dr Glenville 
Jones (Queen’s University Ontario) and Dr Marie Demay (Massachusetts General Hospital) 
and was opened by Dr Darryl Eyles from the University of Queensland in Brisbane, who 
provided an excellent overview of our current understanding of vitamin D signaling in the 
developing brain. Dr Eyles has studied vitamin D metabolism in the brain and the effects of 
hormonal vitamin D on several aspects of neuronal function using cell and animal models. 
Recent work has focused attention on how vitamin D signaling vitamin D regulates the 
synthesis, elimination and signaling of dopamine in developing and adult brains. This was 
followed by a talk by Dr Maria Tamayo (Universidad Autonoma de Madrid, Spain) on the 
beneficial effects of the vitamin D analogue paricalcitol in a setting of cardiac dysfunction 
induced aortic constriction in mice. Evidence was provided that paricalcitol had beneficial 
effects in this model by improving cardiac function and by reversing left ventricular remodeling 
that occurs during heart failure. Normalization of K+ currents was also observed in paricalcitol-
treated animals. Dr Visalin Nair-Shalliker (University of Sydney) presented a talk on a clinical 
study examining the association between post-diagnosis plasma levels of both 25(OH)D3 and 
1,25(OH)2D3 and overall survival of prostate cancer patients in a large Australian cohort, 
PCOSun. The study found that plasma 1,25(OH)2D3 levels interacted significantly with disease 
aggressiveness. Risk of death in men with aggressive prostate cancer was lowest in those 
with 1,25(OH)2D3 levels >106 pmol/L (HR= 0.26; 95%CI: 0.11-0.59). The study concluded that 
high plasma post-diagnostic vitamin D levels is associated with longer overall survival in men 
diagnosed with aggressive prostate cancer. Dr Natalia Carillo-Lopez (Hospital Universitario 
Central de Asturias, Oviedo) then described a study of the potential contribution of defective 
induction by vitamin D of microRNA-145 on the onset and progression of vascular calcification 
in an experimental model of chronic kidney disease. MiRNA-145 is strongly expressed in 
vascular smooth muscle cells, and vascular calcification in chronic kidney disease markedly 
aggravates the risk of cardiovascular mortality. The study found that silencing miR-145 in 
vascular smooth muscle cells exposed to calcifying conditions enhanced expression of marker 
of osteogenic differentiation and increased calcium deposition. Notably, miR-145 ablation also 
compromised the vascular phenotype and increased calcium content under non-calcifying 
conditions. The session closed with a talk from Dr Joseph Bass and colleagues (University 
of Nottingham) on a clinical study of the role of the VDR in regulating skeletal muscle mass. 
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37 individuals underwent 20 weeks of whole-body resistant exercise training. Neither serum 
1,25(OH)2D nor total 25(OH)D3 were associated with VDR or thigh muscle hypertrophy 
responses. However, VDR gene expression positively corresponded with resistance exercise 
training-induced hypertrophy, with the greatest upregulation being observed in high 
responders. Moreover, in animal studies, VDR overexpression in rat hind limbs stimulated 
myofibre hypertrophy, whereas VDR ablation led to muscle atrophy, and evidence was 
provided that autophagy was enhanced in VDR-deficient muscles. 
 
Session VIII on New Functions for vitamin D was chaired by Dr Geert Carmeliet 
(Katholieke Universiteit Leuven) and Dr Rebecca Mason (University of Sydney). The session 
was opened by Dr Motonari Uesugi (Kyoto University) who presented the recently published 
study of his group on 25(OH)D3 acting as an endogenous inhibitor of the cholesterol-sensing 
membrane receptor SREBP [21]. 25(OH)D3 induces proteolytic processing and ubiquitin-
mediated degradation of the SREBP partner protein SCAP. This observation provides the 
opportunity for a pharmacological control of SREBP/SCAP and may lead to a new therapeutic 
approach for lipid disorders. Next a joint talk of Drs Chantal Mathieu and An-Sofie 
Vanherwegen (Katholieke Universiteit Leuven) summarized their findings how vitamin D 
controls the capacity of human dendritic cells to induce functional regulatory T cells by 
regulation of glucose metabolism [22, 23]. They showed that 1,25(OH)2D3 imprints human 
monocyte-derived dendritic cells with tolerogenic properties through the reprogramming of 
their glucose metabolism. The PFKFB4 gene, encoding for a glycolytic enzyme, was identified 
as a primary vitamin D target gene. PFKFB4 inhibition in 1,25(OH)2D3-treated dendritic cells 
blocks their capacity to induce suppressive regulatory T cells, i.e. alterations in the 
bioenergetic metabolism of immune cells are central to the immune-modulatory effects of 
vitamin D. In the same line Amadeo Muñoz García (joint PhD program of the universities of 
Maastricht, Netherlands, and Birmingham, UK) presented his pathway analysis of existing 
transcriptomic datasets for multiple myeloid cell types indicating that innate immune 
responses to 1,25(OH)2D3 in dendritic cells are strongly associated with mitochondrial 
energetic pathways. Results of these bioinformatic predictions were experimentally validated 
by metabolite analysis. Dr Stella Davies (Cincinnati Children’s Hospital, OH, USA) reported 
on vitamin D binding protein (DBP) kinetics in the first 3 months after bone marrow 
transplantation in 131 children. She suggested that DBP modifies survival by i) serving as an 
actin scavenger that removes endothelium-damaging F-actin released into the circulation 
during chemotherapy and ii) by functioning as a macrophage-activating factor. These 
mechanisms may also be relevant in other clinical settings, such as major trauma, sepsis and 
burns. Dr Kay Dube (Ulster University) spoke on the UGT1A gene locus, which encodes for 
a family of phase II metabolism enzymes facilitating the glucuronidation of many endogenous 
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and exogenous substances, as a VDR target. VDR and its ligands markedly enhance the 
expression of several members of the UGT1A gene family and a VDR binding site within the 
regulatory region of the UGT1A1 gene was identified. The capacity for VDR to modulate 
glucuronidation in extra-hepatic tissues suggests a clinical importance of vitamin D in 
hyperbilirubinemia and various cancers. Finally, Dr Sharon Huish (University Hospital of 
Coventry) reported on a study, in which vitamin D3 supplementation corrected vitamin D 
deficiency and decreased erythropoietin needs of 350 hemodialysis patients. This indicates 
that even in end stage renal disease the ability to synthesize 1,25(OH)2D3 is maintained when 
in the presence of adequate substrate is provided. 
 
Session IX, Vitamin D Chemistry and Analogs, was opened by Dr Alexander (Leggy) 
Arnold (University of Wisconsin, Milwaukee) who showed that calcitroic acid, a natural 
1,25(OH)2D3 catabolite, is an inhibitor of P450 enzyme activity. Metabolism of 1,25(OH)2D3 in 
liver microsomes is slowed in the presence of calcitroic acid. Because of it acid functionality, 
calcitroic acid is distributed very differently in the body than 1,25(OH)2D3. The group developed 
a novel LC/MSMS to quantify calcitroic acid in different tissues with low limits of detection. 
This was followed by a talk by Dr Martin Kaufmann (Queen’s University Ontario) on detection 
and quantification in vivo of the C24-oxidation product of 25(OH)D3 in serum of mice treated 
with 24,25(OH)2D3. 25OHD3 is catabolized by CYP24A1 to calcioic acid and excreted. The 
group used followed the multi-step catabolism of vitamin D3 metabolites in vivo using LC-
MS/MS methods based on liquid-liquid- and immuno-extraction approaches. Amplification of 
24,25-(OH)2D3 catabolism by exogenous enabled detection of the complete downstream C24-
oxidation pathway products in vivo, including calcioic acid [24]. The results provide a basis for 
studying alternative routes of vitamin D catabolism that may occur in pathological states. Dr 
Robert Tuckey (University of Western Australia) focused on the catalytic properties of the 
25(OH)D3 3-epimerase in human and rat liver microsomes. The product, 3-epi-25(OH)D3, is 
generally the third most abundant form of vitamin D present in the serum after 25(OH)D3 and 
vitamin D3. 3-epi-1α,25-dihydroxyvitamin D3 has lower biological activity than 1,25(OH)2D3. 
Thus, 3-epimerization causes at least a partial inactivation of the hormone. The gene encoding 
the epimerase has not been identified. The group found that NADH was the preferred co-factor 
for both the human and rat enzymes and that the reverse reaction was catalyzed by both rat 
and human enzymes, but at lower rates than the forward reaction.  
 
The final day of the meeting began with Session X, a plenary talk on A Year in Vitamin D – 
Clinical presented by Dr Peter Ebeling (Monash University). Dr Ebeling began by discussing 
the studies that have led to the description of Hereditary Vitamin D-dependent Rickets Type 3 
(VDDRIII) [25]. As outlined earlier, this is due to mutations in the gene for the enzyme CYP3A4 
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that potently enhance the ability of CYP3A4 to catabolize 25(OH)D3 and 1,25(OH)2D3 to less 
active metabolites, similar to that normally mediated by CYP24A1. The focus of the remainder 
of the talk was the dramatic expansion of observational studies of vitamin D status and 
randomized control trials (RCT) for vitamin D supplementation. A literature search (January 1, 
2013 to March 31, 2018 (Scopus)) revealed 632 publications relating to vitamin D RCT, and 
about 3000 vitamin D RCTs were registered with the ClinicalTrials.gov registry. Several health 
outcomes were included as the primary end-points of these published RCTs: falls, frailty, 
cardiovascular disease, maternal and infant health, musculoskeletal disease, type 2 diabetes 
mellitus, cancer, critical illness, osteoarthritis, respiratory diseases, infection and immunity. Dr 
Ebeling then presented examples of findings from some major trials (selected on the basis of 
>100 participants and numbers of citations). 
Falls/frailty: A 12-month, double blind trial of 200 ambulatory men and women (mean age 78 
years) given monthly 24,000 IU vitamin D3 vs. 60,000 IU vitamin D3, or 24,000 IU vitamin D3 
and 300µg calcifediol [26]. The primary end point [change in Short Physical Performance 
Battery scores (SPPB)] was no different across groups. In fact, repeated chair stands showed 
less improvement in the 60,000 IU and 24,000 IU+ 25(OH)D3 groups. There was an increased 
percentage of fallers in the 60,000 IU and 24,000 IU + 25(OH)D3 groups (67% and 66%, 
respectively, versus 24,000 IU group (48%; p=0.048). Despite the lack of a control group, 
these data suggest monthly high-doses of vitamin D should be avoided in the elderly. A large, 
double blind, placebo-controlled trial (ViDA) enrolled 5108 participants (58% male; mean age 
65.9 years) treated with a 200,000 IU loading dose of cholecalciferol followed by monthly 
100,000 IU doses for a median of 3.3 years. Only approximately 25% of participants were 
vitamin D deficient at baseline. Mean baseline 25(OH)D3 was 63 nmol/L, with only 2% <25 
nmol/L. There was no difference in falls between vitamin D and placebo over up to 4 years of 
follow up. Reported falls were 1312 (52%) vitamin D vs. 1326 (53%) placebo; HR=0.99 (0.92, 
1.07) p=0.82 [27, 28]. 
Cardiovascular Disease: In ViDA there was no difference in incidence of cardiovascular 
disease (CVD) between groups 303 (11.8%) vs. 293 (11.5%); HR=1.02 (95% CI; 0.87, 1.20). 
The primary study outcome was negative, but this outcome focused on a large number of 
different CVD outcomes and it is unlikely that vitamin D deficiency could have benefits for all 
of these [29]. Interestingly, in the same study cohort, analysis of blood pressure showed that 
vitamin D supplementation lowered central BP parameters among adults with vitamin D 
deficiency but not in the cohort as a whole [30]. In the ViDA cohort vitamin D supplementation 
also improved persistence with statins use in older adults on long-term statin therapy, 
suggesting a possible role for vitamin D supplementation as an adjunct therapy for those on 
long-term statins [31]. 
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Musculoskeletal: Amongst the secondary outcomes recorded in the ViDA study, non-vertebral 
fractures were similar; 156 (6%) in vitamin D-supplemented vs. 136 (5%) in placebo groups; 
HR 1·19 (95% CI 0·94–1·50) p=0·15. Interpretation of these outcomes has limitations: 1) these 
were secondary trial outcomes; 2) the trial was underpowered to detect differences in fractures 
(and falls); 3) bolus D dosing was used, which based on recent RCT data in the elderly would 
not now be recommended in that group. 
Cancer: In a large double blind, placebo-controlled trial of 2303 postmenopausal women 
(mean age 65 years), subjects were treated with 2,000 IU cholecalciferol per day and 1500 
mg per day of calcium or placebo for 4 years. Incident cancer was confirmed in 45 (3.9%) in 
the vitamin D group and 64 (5.6%) in placebo [difference, 1.69% (−0.06%, 3.46%); p= 0.06]. 
Kaplan-Meier incidence over 4 years tended to be less in vitamin D vs. placebo; p=0.06. 
Although the study was negative, it does suggest a trend for vitamin D to reduce cancer, which 
needs to be confirmed in larger RCTs [32]. In a Japanese cohort of 33,736 participants 
followed for an average of 15.9 years, with a randomly selected sub-cohort of 4,044 plasma 
25(OH)D was inversely correlated with the risk of total cancer, with multivariable adjusted HR, 
for the highest to lowest quartile of 0.78 (0.67 to 0.91), (P for trend=0.001) [33]. An inverse 
association was found for liver cancer and plasma 25(OH)D, adjusted HR for the highest to 
lowest quartile of 0.45 (0.26 to 0.79), (P for trend=0.006) and for breast cancer in 
premenopausal women (P for trend=0.03). This study suggested that higher vitamin D 
concentrations were associated with a lower risk of total cancer, liver cancer and breast cancer 
in premenopausal women [33]. 
Acute respiratory infections: A large meta-analysis of 25 eligible randomised controlled trials 
showed a 12% decrease with vitamin D (total 11,321 participants, with individual patient data 
obtained for 10,933 (96.6%). Vitamin D reduced the risk of acute respiratory tract infections 
(RTIs) among all participants (OR=0.88, 95% CI 0.81-0.96; p<0.001). Protective effects were 
seen in those receiving daily or weekly vitamin D without additional bolus doses (OR=0.81, CI 
0.72-0.91), but not in those receiving bolus doses. Protective effects were greatest in those 
with baseline serum 25(OH)D3 <25 nmol/L (OR=0.30, CI 0.17-0.53); p interaction=0.006). 
These data show vitamin D supplementation protected against acute RTI, and patients not 
receiving bolus doses and those with severe vitamin D deficiency experienced the most benefit 
[18]. 
Knee osteoarthritis: Two recent systematic reviews and meta-analyses of the effects of vitamin 
D supplementation on knee osteoarthritis, in four RCTs involving 1136 patients, showed 
vitamin D supplementation of more than 2000 IU vitamin D3 per day resulted in small 
decreases in the WOMAC pain score and function in patients with knee OA. However, there 
was no beneficial effect on the prevention of tibial cartilage loss. Therefore, there is currently 
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a lack of evidence to support the use of vitamin D supplementation in preventing the 
progression of knee OA [34].  
Dr Ebeling concluded that there is discordance between the largely negative findings of RCTs 
compared with the outcomes of observational studies associating vitamin D deficiency with 
adverse disease outcomes. Reverse causality with the illness itself contributing to low vitamin 
D levels may explain this. The results of many RCTs have also been inconsistent. However, 
overall evidence from RCTs shows vitamin D reduces fractures (when administered with 
calcium), in the institutionalised elderly, but not in community-dwelling adults. Vitamin D is also 
likely to reduce acute respiratory tract infections (if not given as a bolus dose), and may reduce 
falls in those with the lowest serum 25(OH)D levels. Currently, there is no consistent or 
conclusive evidence for a positive vitamin D impact on other diseases, including cancer, or on 
all-cause mortality.  
 
Session XI chaired by Dr Martin Hewison (University of Birmingham) and Dr Mairead Kiely 
(University College Cork) focused on Vitamin D and Reproduction. Dr Carol Wagner 
(Medical University of South Carolina) discussed the role of vitamin D in preventing health 
disparities during pregnancy, specifically the elevated rates of adverse events of pregnancy 
in African-Americans in the USA. Dr Wagner described three randomized control vitamin D 
supplementation trials. In the first two of these, funded by the Eunice Kennedy Shriver National 
Institute of Child Health and Human Development (n=350), and Thrasher Research Fund 
(n=160), the level of circulating 25(OH)D3 was linked to improved pregnancy outcomes. 
However, poor adherence meant that vitamin D supplementation (versus placebo) did not 
have significant effect on pregnancy outcome. In the third trial, (Funded by WK Kellogg 
Foundation, n=257), 4400 IU/day vitamin D was compared to 400 IU in women with otherwise 
healthy pregnancies (at 8-12 weeks of gestation). The higher dose of vitamin D was not 
associated with improvement in individual pregnancy morbidities, but was associated with 
lower risk (OR=0.26, p=0.034) of combined morbidities (hypertension, diabetes, 
preeclampsia, preterm delivery, chorioamnionitis, miscarriage, intrauterine fetal death, 
bacterial vaginosis) in African-American women. Dr Wagner concluded that higher dose 
supplementation with vitamin D should inform future global health policy surrounding 
pregnancy interventions.  
 
Dr Catherine Hawrylowicz (Kings College London) discussed the impact of vitamin D 
supplementation during pregnancy on pregnancy offspring and, specifically, the neonatal 
immune system. Her studies have focused on how maternal vitamin D status during pregnancy 
can affect asthma-related risk factors and outcomes in later life. In the Vitamin D Antenatal 
Asthma Reduction Trial maternal supplementation with 4,400 IU vitamin D per day (n = 26) 
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was compared to a control arm of treatment with 400 IU vitamin D per day (n = 25). Flow 
cytometric analysis of resulting cord blood immune cells showed enhanced responses to 
mitogen stimulus in cells from women supplemented with the higher level of vitamin D, and a 
corresponding elevation of pathogenic recognition receptors such as toll-like receptors (TLR). 
The conclusion from these studies was that enhanced maternal vitamin D status during 
pregnancy plays a key role in modifying the baby’s immune responsiveness. 
 
Dr Inez Schoenmakers (University of East Anglia) described studies in which her group had 
investigated the relationship between maternal and fetal 25(OH)D3 following maternal vitamin 
D supplementation. In a study of a subset of women (34 weeks gestation) from the MAVIDOS 
trial receiving either placebo or supplementation with vitamin D (1,000 IU/day), maternal and 
cord blood were assessed for various vitamin D metabolites. Maternal and cord concentrations 
of all vitamin D metabolites studied (total and free 25(OH)D3, 3-epi-25(OH)D3 and 
24,25(OH)2D3) were significantly higher with supplementation. Compared to maternal 
concentrations, cord total 25(OH)D3 and 24,25(OH)2D3 were lower, 3-epi-25(OH)D3 
comparable and free 25(OH)D3 higher. These observations indicated that maternal 
concentrations of vitamin D metabolites were not necessarily a direct reflection of the vitamin 
D available to the fetus. Dr Ankana Ganguly (University of Birmingham) described more 
mechanistic studies in which she had investigated the effects of vitamin D on placental 
development, specifically the ability of vitamin D to promote the invasive properties of fetal 
trophoblastic cells. Using cell models of the extravilllos trophoblastic cells that invade maternal 
decidua during placental formation, studies showed that 1,25(OH)2D3 potently stimulated 
matrix invasion. This effect was associated with negligible expression of VDR or CYP24A1 in 
trophoblastic cells, consistent with non-genomic response to 1,25(OH)2D3. By contrast, 
1,25(OH)2D3 inhibited matrix invasion by non-trophoblastic cells in a VDR-specific manner, 
suggesting placenta-specific effects of vitamin D during early pregnancy. In the final 
presentation of this session, Dr Richard Mellanby (University of Edinburgh) described a 
unique model for studying the effects of vitamin D on reproductive health. Wild, unmanaged, 
populations of Soay sheep on the uninhabited Scottish Island of St Kilda were studied between 
2011 and 2016. Total plasma 25(OH)D3 levels in these animals were related to age and color 
of the sheep (with 25(OH)D3 being lower in dark colored sheep). Plasma levels of 25(OH)D3 
predicted fecundity in some years but not in others. The underlying basis for this is unclear 
but may explain the relatively stable distribution of light and dark colored sheep in this wild 
population of animals.  
 
The final section of the meeting, Session XII, was focused on Optimizing Vitamin D and was 
chaired by Dr Klaus Badenhoop (Goethe University Frankfurt am Main) and Dr Dan Bikle 
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(University of California San Francisco). Dr Kevin Cashman (University College Cork) 
provided a comprehensive overview of his work considering individual dose-response data 
compared to aggregated data from intervention trials on the assessment of dietary reference 
values (DRVs) for the population. He showed how considering between-person variability 
influences estimates of DRV using different target values of plasma 25(OH)D3. He also 
considered the potential effects of the frequency, form and mode of vitamin D intake on 
bioavailability and the response in plasma 25(OH)D3 and how this may influence the 
assessment of dietary requirements of the population [35].  
 
Dr Martin Kaufmann (Queen’s University, Kingston) showed a novel approach for the 
differential diagnosis of genetic and non-genetic causes of hypercalcemia by profiling of 6 
vitamin D metabolites (25(OH)D3, 24,25(OH)2D3, 25(OH)D3-26,23-lactone, 23,25,26(OH)3D3, 
1,25(OH)2D3, and 1,24,25(OH)3D3) by LC-MS/MS. Vitamin D metabolite concentrations and 
their ratios were evaluated in groups of patients with known causes of hypercalcemia and also 
after interventions to normalize plasma calcium. This 6-metabolite profiling assists in the 
identification of patients requiring genetic testing and to decide on intervention strategies to 
control hypercalcemia. Dr Rachida Rafic (VU Amsterdam, LUMC, Leiden) showed gender-
dependent relationships between plasma 25(OH)D3 concentrations and different body fat 
deposits (total body, abdominal subcutaneous, visceral and hepatic) in a population-based 
cohort study of adults. Overall, the amount of visceral fat tissue was most strongly negatively 
associated with plasma 25(OH)D3 concentrations. In women, an inverse association with 
plasma 25(OH)D3 was also found for total body fat and for men for hepatic fat.  
Dr Davaasambuu Enkhmaa (National Center for Maternal and Child Health, Mongolia) 
presented data from a dose-ranging vitamin D supplementation trial (600, 2000, or 4000 IU of 
vitamin D3/day) from early pregnancy to delivery in women with from Mongolia, where vitamin 
D status is generally low. A dose-dependent increase in maternal and cord plasma 25(OH)D3 
was found. Although all dosages reduced the percentage of women with a plasma 
concentration below 20 ng/ml compared to baseline (91%), a significantly higher proportion of 
women (56%) had a plasma 25(OH)D3 below 20 ng/ml after supplementation with 600 IU/day 
compared to the higher dosages (16%). Cord blood concentrations of 25(OH)D3 below 50 
nmol/L were found in 83% of the 600 IU/day group, and was significantly lower with the higher 
doses. Dr Rebecca Mason (University of Sydney) provided evidence from in vitro and animal 
models that uptake of 25(OH)D3 in muscle tissue and the cycling of 25(OH)D3 between the 
muscle and blood pool may provide a mechanism to protect against 25(OH)D3 catabolism and 
depletion of bodily stores. Phosphorus depletion disrupts this mechanism; phosphorus 
depleted animals not only have rachitic lesions but also and an increased rate of plasma 
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disappearance of 25(OH)D3. Phosphorus depletion was shown to disrupt 25(OH)D3 uptake 
and release from muscle and leads to altered concentrations of 25(OH)D3 in muscle tissue.  
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